Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas
| Autor: | Werner Boecker, Sören Kneif, Christina Scheel, Frank Berthold, Barbara Dockhorn-Dworniczak, Holger Christiansen, Bernhard Heine, Harald Stein, Karl-Ludwig Schaefer, Christopher Poremba, Barbara Hero, Heribert Juergens |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
Cancer Research Telomerase Protein subunit Bioinformatics Neuroblastoma Humans Gene and protein expression Medicine Telomerase reverse transcriptase Survival rate Neoplasm Staging business.industry Disease progression Infant RNA medicine.disease Gene Expression Regulation Neoplastic Survival Rate Oncology Multivariate Analysis Pediatrics Perinatology and Child Health Disease Progression Cancer research Female business |
| Zdroj: | Medical and Pediatric Oncology. 35:651-655 |
| ISSN: | 1096-911X 0098-1532 |
| Popis: | Background. As traditional parameters do not ensure completely accurate prognostic grouping in neuroblastoma (NB), new molecular markers are needed for assessing the individual patient’s prognosis more precisely. Procedure, Results, and Conclusions. Based on 133 NB, we show that telomerase activity (TA) is a powerful, independent prognostic marker for all stages and is capable of differentiating between good and poor outcome in putative ‘favorable’ clinical or biological subgroups of NB patients. Analysis of gene and protein expression of telomerase subunits suggests that the presence or absence of TA in NB is strongly correlated with expression levels of both the catalytic subunit hTERT and the internal RNA component (hTR). Med. Pediatr. Oncol. 35: 651‐655, 2000. © 2000 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text